Name of Ad
Page number 12
© 2025 Glaukos PM-US-2382 REV.1
Disclosure: The authors are consultants for Glaukos, which supported this white paper.
INDICATIONS
Photrexa® Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5'-phosphate ophthalmic solu-
tion) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal
ectasia following refractive surgery.
IMPORTANT SAFETY INFORMATION
Corneal collagen cross-linking should not be performed on pregnant women.
Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction
was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain,
light sensitivity, reduced visual acuity, and blurred vision.
These are not all of the side effects of the corneal collagen cross-linking treatment. For more information, go to www.Glaukos.com/cornea
to obtain the FDA-approved product labeling.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
The reimbursement codes provided in this article are for informational purposes only and do not provide affirmative instruction as to
which codes and modifiers to use for a particular service, supply, procedure, or treatment and does not constitute advice regarding coding,
coverage, or payment. It is the responsibility of providers to determine and submit appropriate codes, charges, and modifiers for products,
services, supplies, procedures, or treatment furnished or rendered.
*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® system is manufactured by Avedro. Avedro is a wholly owned
subsidiary of Glaukos Corporation.
12
